- Home
- DHC vs AUPH Comparison
DHC vs AUPH Comparison
Compare DHC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHC | AUPH |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | Canada |
| Employees | 585 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | DHC | AUPH |
|---|---|---|
| Price | $8.86 | $16.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $8.00 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $3.13 | $17.54 |
| Revenue Next Year | $7.00 | $15.74 |
| P/E Ratio | ★ N/A | $65.72 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $3.18 | $7.29 |
| 52 Week High | $9.14 | $16.88 |
Technical Indicators
Market Signals| Indicator | DHC | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.87 | 60.55 |
| Support Level | $8.10 | $14.60 |
| Resistance Level | $9.14 | $16.88 |
| Average True Range (ATR) | 0.37 | 0.52 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 76.77 | 86.17 |
Price Performance
Historical ComparisonAbout DHC Diversified Healthcare Trust of Beneficial Interest
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.